Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial

Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial

Seasonal allergic rhinitis (SAR) places a significant socioeconomic burden, particularly on individuals with poorly managed recurrent and severe symptoms despite standard-of-care treatment. Stapokibart, a humanized monoclonal antibody that targets the interleukin (IL)-4 receptor subunit alpha, inhibits its interaction with both IL-4 and IL-13 in type 2 inflammation. Here we aim to assess the efficacy and safety of stapokibart as an add-on therap…

The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine - PressReach

CHENGDU, China, April 5, 2025 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) (“Keymed” or the “Company”) today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its independently developed IL-4Rα antibody stapokibart, for the treatment of moderate-to-severe seasonal allergic rhinitis (SAR). The study, led by Professor Luo Zhang of Beijing Tongren Hospital, Capital Medical U…

The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine

CHENGDU, China, April 6, 2025 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) (“Keymed” or the “Company”) today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its independently developed IL-4Rα antibody stapokibart, for the treatment of moderate-to-severe seasonal allergic rhinitis (SAR). The study, led by Professor Luo Zhang […]